scholarly journals MEDICAL AND STATISTICAL CHARACTERISTICS OF BREAST CANCER IN ST. PETERSBURG FEMALE RESIDENTS

2019 ◽  
Vol 6 (2) ◽  
pp. 32-39
Author(s):  
N. S. Romanenkov ◽  
V. V. Hizha ◽  
K. N. Movchan ◽  
U. M. Morozov ◽  
R. M. Gedgafov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Standard Deviation ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Breast Cancer Incidence ◽  
Incidence Rates ◽  
Statistical Characteristics ◽  
High Tech ◽  
Breast Cancer Patients ◽  
Statistical Parameters

Purpose. To analyze the main medical and statistical parameters, allowing to evaluate the results of breast cancer treatment. Patients and methods. Data on 4689 breast cancer (BC) patients were analyzed retrospectively. Inclusion criteria were: female, residence in St. Petersburg, diagnosis of BC established in 2011, 2012. The study also includes information on the options of BC surgical treatment, one-year mortality in breast cancer patients and index of the contingent accumulation in St. Petersburg in 2011–2017. For statistical data processing Statistica 12.0 for Windows, Population Cancer Register and MedInfo-4 were used. The differences in the groups of studies were considered statistically significant at p < 0.05.Results. The prevalence of breast cancer among women in St. Petersburg varies from 532.6 per 100 000 population in 2011 to 545.00/0000 in 2012. In 2011 the incidence of BC in women in St. Petersburg was 46.210/0000 (standard deviation 1.05) and in 2012 – 49.50/0000 (standard deviation 1.05). The mean age of breast cancer patients is 64 years (standard deviation 12.25). Localization of a tumor in one of the glands was found in 4617 (98.5%) clinical observations. In 2,846 (60.7%) cases, the tumor sizes varied from 2 to 5 cm. Signs of infiltrative ductal carcinoma were histologically verified in 3689 (80%) cases. The proportion of single-stage breast reconstruction after mastectomy in the overall structure of surgeries in breast cancer patients increased in 2011–2017 more than 6.5 times. The 5-year survival rate in study groups was 64.4% and 63.3%. Conclusions The main statistical parameters of medical care (MC) analysis in breast cancer patients in St. Petersburg in 2011–2017 allow to state generally positive trends in the anticancer fight organization. The increase of the breast cancer incidence rates is partly due to the improved quality of examination and treatment of patients through the creation in the city of a system of high-tech MC, as well as to the particularly wary of doctors in detecting breast tumors.

scholarly journals Lifestyle breast cancer patients among Indonesian women: A nationwide survey

2021 ◽  
Vol 10 (4) ◽  
pp. 730
Author(s):  
Solikhah Solikhah ◽  
Khairunnisaa Nuur Aliifah Setyawati ◽  
Monthida Sangruangake
Keyword(s):  
Breast Cancer ◽  
High School ◽  
Cancer Patients ◽  
Breast Cancer Incidence ◽  
Education Level ◽  
Lifestyle Changes ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Major Health Problem ◽  
Significance Level

Recently, cancer is a major health problem in the world. Lifestyle changes and growing urbanization likely led to increasing breast cancer incidence in such in Indonesia. Therefore, this study aimed to explore lifestyle breast cancer patients among Indonesian women. The investigation was a cross-sectional study distributed among 3,392 females drawn from 13 out of 27 provinces in Indonesia. Multiple binary logistic regressions were conducted to investigate breast cancer risk among Indonesian. A significance level of 0.05 was employed in all analysis. Of the 3,392 respondents included in the analysis, more than half (52.71%; n=1,788) was aged 40–49 years old. The most common marital status of the participants was married (98.20%; n=3,331), followed by no smoking (94.69%; n=3,212) and active exercise (62.12%; n=2,107). Education level was significantly associated with breast cancer (AdjOR_Junior high school=0.21; 95%CI=0.06 to 0.70; p&lt;0.01 and AdjOR_senior high school=0.60; 95%CI=0.15 to 2.26; p&lt;0.05). Education level was significantly related to breast cancer. Lifestyle such as smoking and physical activity was suspected to affect breast cancer indirectly.

CLINICAL AND SUBCLINICAL CHARACTERISTICS ON BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES

2021 ◽  
Vol 62 (5) ◽  
Author(s):  
Bui Dang Minh Tri ◽  
Doan Thanh Truc ◽  
Tri Kim Ngoc ◽  
Vo Van Cuong
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Nipple Discharge ◽  
Medullary Carcinoma ◽  
Unknown Boundary ◽  
Age Group ◽  
Breast Cancer Patients ◽  
Research Subjects ◽  
Tubular Carcinoma

Objective: Describing the clinical and subclinical characteristics on breast cancer patients treated with Anthracyclines at Thong Nhat hospital.Subjects and methods: a prospective descriptive study on 43 patients with breast cancer was treated with Anthracyclines with 4 to 6 cycles as determined by clinical doctor at Thong Nhat hospital. Results: Average age: 49.2 ± 3.2 years old. The age group accounted for the largest proportion in the study object was the 50-60 age group (48.84%). The percentage of patients who self-examined the tumor was the highest with 79.07%. There were 9.30% of patients with pain symptoms, 11.63% of patients with nipple discharge. Tumor position in the upper-external quadrant accounted for the largest percentage with 55.81%. The average size of tumors was 2.56 ± 1.2 (cm). The main form of lesions detected on ultrasound was the local lesion with over 80% with an unknown boundaryfeature (81.40%) and predominantly invasive (76.74%). The histopathological type accounted for the highest percentage was the invasive tubular carcinoma (79.07%), the medullary carcinoma andmucinous carcinoma body accounted for the lowest rate with 2.33% and 0%, respectively. The histological degree accounted for the highest percentage among the research subjects was degree 2with 50.18%. Stage III accounted for the highest rate with 46.51%.Conclusion: The most common age group for breast cancer was 50-60 years old, the main symptom was self-examination with breast tumors, breast cancer were mainly local tumor at the upper-externalposition. On ultrasound, the lesions were the local, unknown boundary, and invasive lesions. Breast cancer was mainly invasive ductal carcinoma, histologic degree 2.

Abstract 14206: Assessing a Clinical Risk Score and the Impact of Race in Breast Cancer Patients at Risk of Cardiotoxicity

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Zachary Brumberger ◽  
Mary Branch ◽  
Joseph Rigdon ◽  
Suji Vasu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Risk Score ◽  
Significant Risk ◽  
Statistical Characteristics ◽  
Risk Scores ◽  
Clinical Risk Score ◽  
Breast Cancer Patients ◽  
Clinical Risk ◽  
The Impact

Introduction: Cardiotoxicity is a well-known risk in breast cancer patients treated with anthracyclines and trastuzumab. Ezaz et al. developed a clinical risk score (CRS) to risk stratify these patients. Despite evidence that African American (AA) race is a significant risk factor for cardiotoxicity, no study has assessed the impact of AA race on this CRS. Here we assess the discrimination ability of the Ezaz et al. CRS with the addition of AA race. Methods: This is a retrospective cohort utilizing a registry of 118 patients with stage I-IV breast cancer treated with anthracyclines and/or trastuzumab. Patients without baseline echocardiography data or with baseline LVEF < 50% were excluded. The CRS from Ezaz et al. consisting of age, adjuvant chemotherapy, coronary artery disease, atrial fibrillation or flutter, diabetes mellitus, hypertension, and renal failure was calculated with the addition of AA race. Cardiotoxicity was defined by an LVEF decline of ≥ 10% to LVEF < 53% from baseline. Results: In our 118 patient cohort, the mean age was 59 years, 23 (20%) AA patients, 65 (55%) patients considered low risk (scores of 0-3) and 53 (45%) considered moderate to high risk (scores ≥4). After a follow up of 3 months to 5 years, 14 (12%) patients developed cardiotoxicity. Table 1 lists the CRS changes in statistical characteristics and predictability with the addition of AA race. In comparing the models, the AUC c-statistic increased from 0.609 to 0.642 (95% CI 0.47-0.75, 95% CI 0.49-0.79 respectively; P value = 0.56) with the addition of AA race ( Figure 1 ). Conclusions: In this study, the Ezaz et al. CRS demonstrated improved discrimination and sensitivity with the addition of AA race. This study suggests AA race improves the predictive ability of the Ezaz et al. CRS. Given the limited size of our study, we promote that this should be hypothesis-driving and encourage further investigation on the path to develop an important risk stratification tool.

Serum ANGPTL2 Levels Reflect Clinical Features of Breast Cancer Patients: Implications for the Pathogenesis of Breast Cancer Metastasis

2014 ◽  
Vol 29 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Motoyoshi Endo ◽  
Yutaka Yamamoto ◽  
Masahiro Nakano ◽  
Tetsuro Masuda ◽  
Haruki Odagiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Features ◽  
Cancer Progression ◽  
Breast Cancer Cells ◽  
Cancer Metastasis ◽  
Ductal Carcinoma ◽  
Breast Cancer Metastasis ◽  
Breast Cancer Patients

Introduction Breast cancer is a leading cause of cancer-related death in women worldwide, and its metastasis is a major cause of disease mortality. Therefore, identification of the mechanisms underlying breast cancer metastasis is crucial for the development of therapeutic and diagnostic strategies. Our recent study of immunodeficient female mice transplanted with MDA-MB231 breast cancer cells demonstrated that tumor cell-derived angiopoietin-like protein 2 (ANGPTL2) accelerates metastasis through both increasing tumor cell migration in an autocrine/paracrine manner, and enhancing tumor angiogenesis. To determine whether ANGPTL2 contributes to its clinical pathogenesis, we asked whether serum ANGPTL2 levels reflect the clinical features of breast cancer progression. Methods We monitored the levels of secreted ANGPTL2 in supernatants of cultured proliferating MDA-MB231 cells. We also determined whether the circulating ANGPTL2 levels were positively correlated with cancer progression in an in vivo breast cancer xenograft model using MDA-MB231 cells. Finally, we investigated whether serum ANGPTL2 levels were associated with clinical features in breast cancer patients. Results Both in vitro and in vivo experiments showed that the levels of ANGPTL2 secreted from breast cancer cells increased with cell proliferation and cancer progression. Serum ANGPTL2 levels in patients with metastatic breast cancer were significantly higher than those in healthy subjects or in patients with ductal carcinoma in situ or non-metastatic invasive ductal carcinoma. Serum ANGPTL2 levels in patients negative for estrogen receptors and progesterone receptors, particularly triple-negative cases, reflected histological grades. Conclusions These findings suggest that serum ANGPTL2 levels in breast cancer patients could represent a potential marker of breast cancer metastasis.

Bilateral breast cancer: a case study

2019 ◽  
Vol 19 (3) ◽  
pp. 305-308
Author(s):  
Rajanigandha Tudu ◽  
Anup Kumar ◽  
Rashmi Singh ◽  
Payal Raina
Keyword(s):  
Breast Cancer ◽  
Primary Breast Cancer ◽  
Breast Cancer Incidence ◽  
Bilateral Breast Cancer ◽  
Late Presentation ◽  
Incidence Rates ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Screening Guidelines ◽  
Cancer Management

AbstractBackground:Breast cancer is the most common cancer among females worldwide. Increasing breast cancer incidence rates, improved diagnosis and management modalities and growing life expectancy have resulted in increasing numbers of women at risk of developing contralateral primary breast cancer. Bilateral breast cancer can occur synchronously or metachronously.Material and methods:This study reports three cases of bilateral breast cancer patients treated at our oncology department between March 2018 and March 2019. The features of presentation, investigation, diagnosis and follow-up care are the highlights of this study.Results:Bilateral breast cancer was noted in three patients among the study population in the age group of 35 –55 years. Two of these patients had metachronous bilateral breast cancer, and one patient developed cancer in the second breast during the course of management. The second breast cancers differed histologically from primary breast cancer.Conclusion:Poor awareness on breast cancer care and the lack of national screening guidelines and programmes, and poor infrastructure, all contribute to late presentation and difficult breast cancer management. Proper history, clinical examination and imaging of opposite breast should be done to ensure adequate and timely management of bilateral breast cancer.

The analysis of NBS-1 gene mutation [657del(5)] in exon 6 in the population of 472 sporadic breast cancer patients in the Czech Republic

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20087-20087
Author(s):  
J. Melter ◽  
G. Pazdrova ◽  
F. Janku ◽  
Z. Kleibl ◽  
J. Novotny ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Internal Control ◽  
Sporadic Breast Cancer ◽  
Breast Cancer Incidence ◽  
Published Data ◽  
Agarose Gel ◽  
Breast Cancer Patients ◽  
Blood Monocytes ◽  
Specific Band

20087 Background: Nijmegen breakage syndrome (NBS) caused by mutation [657del(5)] in exon 6 of NBS-1 is an autosomal recessive disorder with microcephaly, immunodeficiency, radiosensitivity, and predisposition to lymphoid malignancies. Recently, high frequency of NBS-1 mutation was found in some Slavic populations. Because NBS-1 heterozygotes may have high incidence of neoplastic changes, there is an urgent need to clarify the role of NBS-1 mutation in breast cancer carcinogenesis. Methods: We analyzed the NBS-1 status in 472 sporadic breast cancer patients treated in the Department of Oncology, Charles University Prague. DNA was extracted from peripheral blood monocytes. Subsequently two PCRs for each sample were carried out. Reaction was visualized using electrophoresis on agarose gel. Agarose gel wells with both the NBS-1 gene-specific band and internal control band were interpreted as positive. Wells with internal control only were interpreted as negative. PCR from samples giving neither an internal control band nor specific band were repeated. DNA samples obtained from a previously typed NBS family were used as a positive control. Results: Based on previously published data we expect to find at least 5 mutation carriers. Surprisingly, in our population of 472 subjects there was no mutation identified. Conclusions: Based on results of this study there is no relationship between NBS-1 mutation and breast cancer incidence. Acknowledgment: The study was supported in part by the RASO grant from Czech Society of Oncology, and MSM0021620808. No significant financial relationships to disclose.

Early-stage male breast cancer: A 10-year experience

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11630-e11630
Author(s):  
N. Gercovich ◽  
E. Gil Deza ◽  
M. Russo ◽  
C. Garcia Gerardi ◽  
C. Diaz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Male Breast ◽  
Stage I ◽  
Stage Ii ◽  
Breast Cancers ◽  
Breast Cancer Patients

e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases. Objective: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008. Methods: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients. A database was designed following the recommendations of the Directors of Surgical Pathology of the USA. The information registered encompassed: adjuvant treatments, recurrence date and date of final consultation or death. Results: Twelve pts were identified. Mean age (range)= 66 yo (50–89 yo). Tumoral type= Invasive Ductal Carcinoma 12 pt. Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%). Nottingham´s grade= Grade 2: 8 pt, Grade 3: 3 pt, N/A=1 pt. Stage= I= 6 pt, II=6 pt. ER (Positve= 9 pt, Negative=1 pt, N/A= 2 pt). PR (Positve= 8 pt, Negative= 2 pt, N/A=2 pt). Her2neu (0+= 3 pt, 1+= 3 pt, 2+= 2 pt, N/A= 4 pt). Surgery= Mastectomy= 11 pt, Lumpectomy 1= pt. Radiotherapy=5 pt. Adjuvance= No=2 pt, Hormonotherapy (HT)= 3 pt, Chemotherapy (CHT) = 3 pt, CHT+HT= 4 pt. Recurrence= Yes= 2 pt, No= 10 pt. Survival: Dead= 1 pt, Alive =11 pt. Mean Time To Progression= Stage I =66 months, Stage II =42 months. Global survival: Stage I =66 months, Stage II =52 months. Conclusions: 1. Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM. 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3. Ten pt underwent adjuvant treatment. 4. With a mean follow up time of 60 months, all stage I patients are alive and there were no recurrences. Two of the 6 stage II pts progressed and one died. No significant financial relationships to disclose.

Management of octogenarians with female breast cancer in a rural oncology program.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e16513-e16513
Author(s):  
Mir Asif Alikhan ◽  
Dianne L Limesand ◽  
Mark Schmelzel ◽  
Thomas McGlone ◽  
David Powers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Stage Iii ◽  
Adjuvant Radiation ◽  
Breast Cancer Patients ◽  
Co Morbidity ◽  
Her 2

e16513 Background: Despite the fact that chronological age alone does not determine tolerance to cancer treatment, there is a general perception that elderly cancer patients do not receive standard treatment. We sought to review breast cancer patients above 80 years in our practice. Methods: Retrospective analysis was performed ofall women with breast cancer over the age of 80 either at the time of diagnosis or at the time of relapse since July 2005 till July 2011. Results: There were total of 492 breast cancer patients seen during the study period, 207 below 65, 213 between 66-79 and 70 above 80. 59 women met the study criteria. The median age was 86 (81to 99 years). 47 had activities of independent living, 8 were in an assisted living facility and 4 in nursing homes. Median Charlson Co morbidity Index was 2 (0-5). Pathological types: DCIS 2, Invasive ductal carcinoma 50, invasive lobular carcinoma 6 and 1 had apocrine carcinoma. 50 had ER+, PR+ and Her-, 2 patients had triple negative disease and 4 Her+. 2 patients had stage 0, 22 stage I, 23 Stage II, 7 stage III and 5 stage IV. All patients stage 0-III had surgical management, 39 had breast conservative surgery with sentinel node biopsy and 15 had mastectomy. Out of 28 patients referred for adjuvant radiation therapy 17 received it. 49 patients received hormone treatment (39 aromatase inhibitors- AIs and 14 tamoxifen) Chemotherapy was offered but refused by two stage III patients. 2 Her + patients received and tolerated well trastuzumab based chemotherapy. After a median follow up of 48 months (8-120 months) there was 1 local recurrence, 1 distant relapse and 14 deaths ( 11 from other causes 3 from breast cancer). Conclusions: In ourpractice, a majority of octogenarians and nonagenarians live independently and have minimal co morbidities and tolerate standard surgical and hormonal treatment. Although radiation therapy would be considered optional in this group of women, it was offered based on predicted longevity. Mortality form other causes was higher than that from breast cancer ( 18% vs 5%).

Breast cancer patients' rights: How can they be respected in Iran?

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 81-81
Author(s):  
Azadeh Joulaee ◽  
Soodabeh Joolaee ◽  
Naser Bahrani ◽  
Maryam Kadivar ◽  
Mojgan Kalantari
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Care Delivery ◽  
Frozen Section ◽  
Breast Cancer Incidence ◽  
Conservative Surgery ◽  
Published Data ◽  
Breast Cancer Patients ◽  
Patients Rights ◽  
Trucut Biopsy

81 Background: The revolutionary concept in breast cancer diagnosis and treatment has significantly changed many aspects of cancer treatment in favor of patients' rights. The best useful targeted treatment is offered to them with the least harm and invasion. As the most common cancer, breast cancer incidence is 24/100, 000 or one-fourth of all new cancers. The aim of this study is to compare the international rights for breast cancer patients with actual situation in Iran. Methods: All published data in Iran are reviewed since 2001 to 2012 to see the actual care in Iran. Codification of new radiology, surgical and pathologic procedure and insurance coverage are searched through available national references. These data are compared with international references. Results: Diagnosis is done by excisional/incisional biopsy or frozen section. Trucut biopsy is done in a low minority of cases. Insurance system does not cover vacuum assisted biopsy. Only mastectomy and axillary dissection are accepted by insurance. No codification exists for conservative surgery, oncoplastic surgery and sentinel node biopsy and the rate for these surgeries are low. Breast reconstruction, conservative surgery as bilateral mammoreduction, and symmetrization of controlateral breast are considered as cosmetic surgery with no coverage. The majority of cases are treated in general surgical wards. There are very few breast nurses and few centers for rehabilitation, lymphedema treatment, and psychological support of survivor. Conclusions: The ministry of health insists on full respection of the patient’s rights in medical practice. The new rights of breast cancer patients based on new treatment strategy are not highlighted in Iran. Valid evidence must be provided for policy makers about the rights of these vulnerable patients to consider them in Iranian health care delivery system. Specialized breast unit can improve significantly the quality of breast cancer care toward the patients' right. Pre-operative confirmation of cancer by trucut biopsy seems to be the key point. This gives the patient the opportunity to know more about the disease and to search for the best therapeutic plan according to international guideline.

Investigation of potential salivary biomarkers for the diagnosis of breast cancer.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 145-145 ◽  
Author(s):  
Hiromitsu Jinno ◽  
Takeshi Murata ◽  
Makoto Sunamura ◽  
Masahiro Sugimoto
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Biological Fluid ◽  
Neoadjuvant Treatment ◽  
Human Saliva ◽  
Breast Cancer Patients ◽  
Operating Characteristics ◽  
Salivary Biomarkers

145 Background: Saliva is an easily accessible and informative biological fluid which has high potential for the early diagnosis of diseases. Saliva-based diagnostics, particularly those based on metabolomics technology, offer a promising clinical strategy by characterizing the association between salivary analysts and a particular disease. The aim of this study is to investigate potential biomarkers in human saliva to facilitate the early diagnosis of breast cancer. Methods: We conducted a comprehensive metabolite analysis of saliva samples obtained from 60 breast cancer patients and 20 healthy controls, using capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS). Statistical analyses were performed by using a nonparametric Mann-Whitney U test, multiple logistic regression and the receiver operating characteristics (ROC) to evaluate the predictive power of biomarkers. Results: Forty-nine patients (81.7 %) had invasive ductal carcinoma (IDC) and 9 patients (15.0 %) had ductal carcinoma in situ. In 33 patients receiving neoadjuvant treatment, saliva samples were obtained just before surgery. After removing the concomitantly observed peaks and noise peaks, an average of 205 peaks were derived from the metabolites. Among these peaks, five potential salivary biomarkers demonstrated significantly higher concentrations in breast cancer patients comparing with healthy individuals (p < 0.05). Especially, salivary biomarkers obtained from patients with IDC before neoadjuvant treatments tended to be higher concentrations than those obtained after treatment. In these metabolites, the area under the ROC curves (AUCs) were 0.765 for substance A, 0.716 for substance B, 0.809 for substance C, 0.819 for substance D and 0.850 for substance E. Conclusions: Salivary metabolites are promising biomarkers for the early diagnosis of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document